Literature DB >> 31028452

Disability in idiopathic inflammatory myopathies: questionnaire-based study.

Aleksandra Halina Opinc1, Olga Elżbieta Brzezińska1, Joanna Samanta Makowska2.   

Abstract

Idiopathic inflammatory myopathies (IIM) are progressive, debilitating diseases that can lead to severe impairment. The aim of the study was to evaluate the level of disability and compare it between different subtypes of IIM as well as to estimate clinical symptoms associated with greater risk of disability and distinguish the most troublesome activities in this group of patients. A online form concerning clinical symptoms, comorbidities and limitations in daily living was created and distributed to online support groups for patients with IIM. Health Assessment Questionnaire was used to estimate disability and physical limitations while visual analogue scales enabled to assess the intensity of clinical symptoms. 361 out of 377 responders were included for further evaluation. High prevalence of disability was observed in each subtype yet predominantly in patients with inclusion body myositis (IBM) as 51.43% of them fulfilled the criteria of severe to very severe disability. Level of disability correlated with muscle weakness, tolerance of physical activity and level of fatigue. 45.62% of responders in general required walking devices and 43.50% of participants declared using facilitating devices for maintaining hygiene. Patients with IIM encounter multitude physical limitations that can be partially compensated by usage of facilitating devices or aid of the caregivers. IBM seems to be the most disabling subtype.

Entities:  

Keywords:  Disability; Health Assessment Questionnaire; Idiopathic inflammatory myopathy; Myositis

Mesh:

Year:  2019        PMID: 31028452     DOI: 10.1007/s00296-019-04302-y

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  18 in total

Review 1.  Update on outcome assessment in myositis.

Authors:  Lisa G Rider; Rohit Aggarwal; Pedro M Machado; Jean-Yves Hogrel; Ann M Reed; Lisa Christopher-Stine; Nicolino Ruperto
Journal:  Nat Rev Rheumatol       Date:  2018-04-12       Impact factor: 20.543

2.  A 12-year follow-up in sporadic inclusion body myositis: an end stage with major disabilities.

Authors:  Fieke M Cox; Maarten J Titulaer; Jacob K Sont; Axel R Wintzen; Jan J G M Verschuuren; Umesh A Badrising
Journal:  Brain       Date:  2011-09-09       Impact factor: 13.501

3.  Long-term outcome in polymyositis and dermatomyositis.

Authors:  I M Bronner; M F G van der Meulen; M de Visser; S Kalmijn; W J van Venrooij; A E Voskuyl; H J Dinant; W H J P Linssen; J H J Wokke; J E Hoogendijk
Journal:  Ann Rheum Dis       Date:  2006-04-10       Impact factor: 19.103

Review 4.  Novel insights of disability assessment in adult myositis.

Authors:  Hector Fabricio Espinosa-Ortega; Mariana Moreno-Ramirez; Helene Alexanderson
Journal:  Curr Opin Rheumatol       Date:  2017-11       Impact factor: 5.006

5.  Long-term observational study of sporadic inclusion body myositis.

Authors:  Olivier Benveniste; Marguerite Guiguet; Jane Freebody; Odile Dubourg; Waney Squier; Thierry Maisonobe; Tanya Stojkovic; Maria Isabel Leite; Yves Allenbach; Serge Herson; Stefen Brady; Bruno Eymard; David Hilton-Jones
Journal:  Brain       Date:  2011-10-12       Impact factor: 13.501

Review 6.  Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies.

Authors:  F W Miller; L G Rider; Y L Chung; R Cooper; K Danko; V Farewell; I Lundberg; C Morrison; L Oakley; I Oakley; C Pilkington; J Vencovsky; K Vincent; D L Scott; D A Isenberg
Journal:  Rheumatology (Oxford)       Date:  2001-11       Impact factor: 7.580

Review 7.  Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF-36), Child Health Questionnaire (CHQ), physician global damage, Myositis Damage Index (MDI), Quantitative Muscle Testing (QMT), Myositis Functional Index-2 (FI-2), Myositis Activities Profile (MAP), Inclusion Body Myositis Functional Rating Scale (IBMFRS), Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), Cutaneous Assessment Tool (CAT), Dermatomyositis Skin Severity Index (DSSI), Skindex, and Dermatology Life Quality Index (DLQI).

Authors:  Lisa G Rider; Victoria P Werth; Adam M Huber; Helene Alexanderson; Anand Prahalad Rao; Nicolino Ruperto; Laura Herbelin; Richard Barohn; David Isenberg; Frederick W Miller
Journal:  Arthritis Care Res (Hoboken)       Date:  2011-11       Impact factor: 4.794

8.  Clinical characteristics and favorable long-term outcomes for patients with idiopathic inflammatory myopathies: a retrospective single center study in China.

Authors:  Xiao Ming Shu; Xin Lu; Yao Xie; Guo Chun Wang
Journal:  BMC Neurol       Date:  2011-11-09       Impact factor: 2.474

9.  Measurement of patient outcome in arthritis.

Authors:  J F Fries; P Spitz; R G Kraines; H R Holman
Journal:  Arthritis Rheum       Date:  1980-02

Review 10.  Health-Related Quality of Life (HRQoL) in Idiopathic Inflammatory Myopathy: A Systematic Review.

Authors:  Valérie Leclair; Malin Regardt; Sophie Wojcik; Marie Hudson
Journal:  PLoS One       Date:  2016-08-09       Impact factor: 3.240

View more
  6 in total

Review 1.  Assessment of Physical Activity and Muscle Function in Adult Inflammatory Myopathies.

Authors:  William J Gregory; Didem Saygin
Journal:  Curr Rheumatol Rep       Date:  2022-03-04       Impact factor: 4.592

2.  High-Dimensional Analysis Reveals Distinct Endotypes in Patients With Idiopathic Inflammatory Myopathies.

Authors:  Erin M Wilfong; Todd Bartkowiak; Katherine N Vowell; Camille S Westlake; Jonathan M Irish; Peggy L Kendall; Leslie J Crofford; Rachel H Bonami
Journal:  Front Immunol       Date:  2022-02-21       Impact factor: 8.786

3.  Functioning in adult patients with idiopathic inflammatory myopathy: Exploring the role of environmental factors using focus groups.

Authors:  I Armadans-Tremolosa; G Guilera; M Las Heras; A Castrechini; A Selva-O'Callaghan
Journal:  PLoS One       Date:  2021-02-11       Impact factor: 3.240

4.  Feasibility of a blended therapy approach in the treatment of patients with inflammatory myopathies.

Authors:  Pierrette Baschung Pfister; Ruud H Knols; Rob A de Bie; Eling D de Bruin
Journal:  Arch Physiother       Date:  2021-05-27

5.  Underdiagnosis of cardiopulmonary involvement in patients with idiopathic inflammatory myopathies.

Authors:  Aleksandra Opinc; Olga Brzezińska; Joanna Makowska
Journal:  Reumatologia       Date:  2021-11-07

6.  Patient insights on living with idiopathic inflammatory myopathy and the limitations of disease activity measurement methods - a qualitative study.

Authors:  Alexander Oldroyd; William Dixon; Hector Chinoy; Kelly Howells
Journal:  BMC Rheumatol       Date:  2020-09-21
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.